Cited by 396Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

Open access
Huang, Xu, Wullschleger, Stephan, Shpiro, Natalia, McGuire, Victoria A., Sakamoto, Kei, Woods, Yvonne L., Mcburnie, Wendy, Fleming, Stewart +1 more·2008·Biochemical Journal

Abstract

The LKB1 tumour suppressor phosphorylates and activates AMPK (AMP-activated protein kinase) when cellular energy levels are low, thereby suppressing growth through multiple pathways, including inhibiting the mTORC1 (mammalian target of rapamycin complex 1) kinase that is activated in the majority of human cancers. Blood glucose-lowering Type 2 diabetes drugs also induce LKB1 to activate AMPK, indicating that these compounds could be used to suppress growth of tumour cells. In the present study, we investigated the importance of the LKB1-AMPK pathway in regulating tumorigenesis in mice resulting from deficiency of the PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor, which drives cell growth through overactivation of the Akt and mTOR (mammalian target of rapamycin) kinases. We demonstrate that inhibition of AMPK resulting from a hypomorphic mutation that decreases LKB1 expression does not lead to tumorigenesis on its own, but markedly accelerates tumour development in PTEN(+/-) mice. In contrast, activating the AMPK pathway by administration of metformin, phenformin or A-769662 to PTEN(+/-) mice significantly delayed tumour onset. We demonstrate that LKB1 is required for activators of AMPK to inhibit mTORC1 signalling as well as cell growth in PTEN-deficient cells. Our findings highlight, using an animal model relevant to understanding human cancer, the vital role that the LKB1-AMPK pathway plays in suppressing tumorigenesis resulting from loss of the PTEN tumour suppressor. They also suggest that pharmacological inhibition of LKB1 and/or AMPK would be undesirable, at least for the treatment of cancers in which the mTORC1 pathway is activated. Most importantly, our results demonstrate the potential of AMPK activators, such as clinically approved metformin, as anticancer agents, which will suppress tumour development by triggering a physiological signalling pathway that potently inhibits cell growth.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bj20080557

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 50 · Cited by 396

Authors
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R.
Affiliations
University of Dundee (GB)
Corresponding author
  • Huang, Xu
  • Wullschleger, Stephan
  • Shpiro, Natalia
  • Sakamoto, Kei
Venue
Biochemical Journal
Published
2008-05-14
Volume
412
Issue
2
Pages
211-221
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W2037177985
Cited by
396
References
50
Citations by year
2026: 4 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 15 · 2021: 18 · 2020: 13 · 2019: 12 · 2018: 15 · 2017: 27 · 2016: 16 · 2015: 35 · 2014: 42 · 2013: 36 · 2012: 31
FWCI
15.21
Type
journal article
Language
en
Open access
Locations
  • Biochemical Journal (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion, other-oa)
Funders
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • University of Dundee
  • Merck KGaA
  • Diabetes UK
  • Tenovus
  • Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
LKB1, AMPK, PTEN loss, carcinogenesis, mTORC1 signaling, Akt signaling, metformin, phenformin, A769662, AMPK activators, cancer therapy, type 2 diabetes drugs
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Adenylate Kinase, Animals, Cell Line, Enzyme Activation, Female, Humans, Male, Mice, Inbred C57BL, Neoplasms, Protein Kinases, Proteins, Transcription Factors, Signal Transduction, Protein Serine-Threonine Kinases, Mice, Knockout, Tumor Suppressor Proteins, Multiprotein Complexes, PTEN Phosphohydrolase, Mice, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review